呼吸器感染症に対するcefluprenamの臨床的検討  [in Japanese] Clinical studies on cefluprenam in respiratory tract infections  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

新しく開発された注射用セフェム剤cefluprenamを肺炎1例, 肺化膿症1例, 気管支拡張症の急性増悪2例, 感染を伴った肺気腫, 肺線維症各1例の計6例に投与し, 有効性と安全性の検討を行った。投与方法は1回1g, 1日2回, 7~21日間点滴静注した。臨床効果は肺化膿症の1例が無効であったが, 他の5例はすべて有効以上であった。起炎菌は5例で検出され, <I>Haemophilus parainfluenzae</I>1株, <I>Klebsiella pneumoniae</I>1株, <I>Proteus mirabilis</I>1株, <I>Pseudomonas aeruginosa</I>2株はすべて消失した。副作用および臨床検査値異常は認められなかった。

Efficacy and safty of cefluprenam (CFLP) were evaluated on 6 cases comprising 1 pneumonia, 1 lung abscess, 2 bronchiectasis with infection, 1 pulmonary fibrosis with infection and 1 pulmonary emphysema with infection.CFLP was administered intravenously at a dosage of lg twice a day in the morning and evening for 7 to 21 days.Clinical responses were excellent or good in 5 cases but poor in 1 case with lung abscess.<BR>The causative organisms comprizing 1 <I>Haemophilus parainfluenzae</I>, 1 <I>Klebsiella pneumoniae</I>, 1 <I>Proteus mirabilis</I> and 2 <I>Pseudomonas aeruginosa</I> were eradicated. No adverse drug reactions and abnormal laboratory changes were observed.

Journal

  • Japanese Journal of Chemotherapy

    Japanese Journal of Chemotherapy 43, 310-312, 1995-11-30

    Japanese Society of Chemotherapy

References:  3

Codes

Page Top